<DOC>
	<DOCNO>NCT00941356</DOCNO>
	<brief_summary>Trial Objectives : Primary objective : - To evaluate efficacy Bio-K+CL1285® patient Methicillin-Resistant S. aureus ( MRSA ) nasal colonization compare MRSA decolonization follow either Bio-K+CL1285® placebo treatment . Secondary objective : - To evaluate safety profile Bio-K+CL1285® .</brief_summary>
	<brief_title>Evaluation Efficacy Bio-K+ Cl-1285® In Nasal Decolonization Methicillin Resistant Staphylococcus Aureus ( MRSA ) Carrier Patients</brief_title>
	<detailed_description>Study Design : Double-blind , randomize ( 1:1 randomization ) , placebo-controlled , single center Canadian study . Patients randomly assign one two study product . A randomization schedule generate sponsor participate centre . This schedule link patient identification number one two study product allocate random . The schedule prepare 1:1 randomization ratio . The study product label patient identification number . Patients randomized order qualify screen phase inclusion study . Patients withdraw study retain patient number already give . New patient must always allot new identification number ( PIN ) . Study Duration : The duration patient participation study 22 23 day . The overall duration study expect approximately 10 month ; subject recruitment propose start March 2009 , last follow-up visit expect May 2010 . The actual overall study duration subject recruitment period may vary . Number Sites ( inside outside Canada ) : One center province Quebec involve study .</detailed_description>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<criteria>Male female patient ≥18 year age Women child bear capacity pregnant moment screening ( Pregnancy test do onsite ) agree use acceptable form birth control duration study ( e.g . condom , oral contraceptive , etc . ) allow participate . Patients must nasal MRSA colonization confirm MRSA positive culture assess screen visit without clinical sign symptom infection . Laboratory test result within normal range . Ability understand willingness sign write informed consent document . Patients treat nasal MRSA decolonization last 6 month ; Current infection MRSA ; Ongoing active infection ; Daily probiotic/ ferment milk Yogurt use ; Known show previous reaction , include anaphylaxis , substance composition study agent ( capsule ) ; Ongoing recent use antibiotic 30 day prior study agent administration ; Pregnancy , breastfeeding ; Regular use nasal agent ; Uncontrolled intercurrent illness , include situation would limit compliance study requirement ; Patients open wound Immunosuppressive therapy health condition cause inmunosuppression ( Including Haematological malignancy , AIDS ) ; Ostomized patient , parenteral nutrition user ; Patients current vascular access ( catheter ) plan installed vascular access ( catheter ) prosthesis study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>MRSA nasal colonisation</keyword>
	<keyword>Probiotics</keyword>
</DOC>